GSK Wins Early FDA Nod for Nelkarmi
GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.
How this was made

The 30-second read
Why it matters
The approval advances GSK’s lung cancer franchise timeline and provides a near-term commercialization catalyst, but the conditional nature and liver-toxicity signal keep fundamental upside dependent on confirmatory evidence.
Market read
Traders can reassess GSK’s oncology launch optionality immediately, while also re-evaluating the probability-weighted path to confirmatory trial success given the safety profile.
What to watch
Hepatotoxicity is the main safety signal with 5% permanent discontinuations, which could constrain uptake and increase post-launch monitoring or label refinement risk.
Background
Nelkarmi (neladalkib) received accelerated US approval for previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 phase I/II data.
Ticker impact
GSK says the FDA granted accelerated US approval for its lung cancer drug Nelkarmi (neladalkib) for previously treated ALK-positive NSCLC.
Likely upward bias as traders price in earlier commercialization optionality, while investors may discount some upside due to conditional approval and safety discontinuation risk.
The article is a first-report style regulatory approval with specific label, trial basis, response rates, and a stated safety signal, which directly affects GSK’s near-term risk-reward for Nelkarmi.
Market effects
Reinforces investor appetite for ALK-targeted lung cancer assets and highlights the market’s focus on accelerated-approval durability and safety management.
Supports UK pharma sentiment via a US regulatory win, potentially improving cross-Atlantic biotech risk appetite.
US FDA oncology approvals can shift global expectations for ALK franchise competitiveness and trial read-throughs.
Counterpoint
Because the approval is accelerated and conditional on confirmatory trials, the market may treat it as incremental until ALKAZAR (phase III) validates benefit and tolerability.
Key entities
- companyGSK
London-listed drugmaker receiving accelerated FDA approval for Nelkarmi.
- regulatorFDA
US drug regulator granting accelerated approval ahead of the target date.
- drugNelkarmi (neladalkib)
GSK lung cancer drug cleared for previously treated ALK-positive NSCLC under accelerated approval.
- clinical_trialALKOVE-1
Phase I/II trial supporting the accelerated approval, with response rates reported by prior treatment group.
- clinical_trialALKAZAR
Phase III trial in patients who have not had a TKI before, cited as part of the commercial case.




